Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients

Abstract

Thiazolidinediones (TZDs) improve glycemic control and insulin sensitivity in patients with type 2 diabetes. To determine whether the TZD-induced improvement in glycemic control is associated with enhanced insulin receptor signaling in skeletal muscle, 20 type 2 diabetic patients received a 75-g oral glucose tolerance test (OGTT) and euglycemic insulin (80 mU · m−2 · min−1) clamp with [3-3H]glucose/indirect calorimetry/vastus lateralis muscle biopsies before and after 16 weeks of rosiglitazone treatment. Six age-matched nondiabetic subjects served as control subjects. RSG improved fasting plasma glucose (185 ± 8 to 139 ± 5 mg/dl), mean plasma glucose during the OGTT (290 ± 9 to 225 ± 6 mg/dl), HbA1c (8.5 ± 0.3 to 7.1 ± 0.3%), insulin-mediated total-body glucose disposal (TGD) (6.9 ± 0.7 to 9.2 ± 0.8 mg · kg−1 fat-free mass · min−1) (all P < 0.001), and decreased fasting plasma free fatty acid (FFA) (789 ± 59 to 656 ± 50 μEq/l) and mean FFA during the OGTT (644 ± 41 to 471 ± 35 μEq/l) (both P < 0.01). Before RSG treatment, insulin infusion did not significantly increase insulin receptor tyrosine phosphorylation (0.95 ± 0.10 to 1.08 ± 0.13 density units; NS) but had a small stimulatory effect on insulin receptor substrate (IRS)-1 tyrosine phosphorylation (1.05 ± 0.10 to 1.21 ± 0.12 density units; P < 0.01) and the association of p85 with IRS-1 (0.94 ± 0.06 to 1.08 ± 0.06 activity units; P < 0.01). RSG therapy had no effect on basal or insulin-stimulated insulin receptor tyrosine phosphorylation but increased insulin stimulation of IRS-1 tyrosine phosphorylation (1.13 ± 0.11 to 1.56 ± 0.17 density units; P < 0.01 vs. prerosiglitazone) and p85 association with IRS-1 (1.00 ± 0.06 to 1.27 ± 0.07 activity units; P < 0.05 vs. prerosiglitazone). In control and type 2 diabetic subjects, TGD/nonoxidative glucose disposal correlated positively with the insulin-stimulated increments in IRS-1 tyrosine phosphorylation (r = 0.52/r = 0.57, P < 0.01) and inversely with the plasma FFA concentration during the insulin clamp (r = −0.55/r = −0.53, P < 0.01). However, no significant association between plasma FFA concentrations during the insulin clamp and the increment in either IRS-1 tyrosine phosphorylation or the association of p85 with IRS-1 was observed. In conclusion, in type 2 diabetic patients, rosiglitazone treatment enhances downstream insulin receptor signaling in muscle and decreases plasma FFA concentration while improving glycemic control.